INOZYME PHARMA INC. -

Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency

09 июн 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights

12 май 2021 05:00:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

07 май 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference

06 май 2021 06:30:01 Источник Nasdaq GlobeNewswire

Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency

29 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences

28 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics

14 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics Meeting

08 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Expands its Scientific Advisory Board

01 апр 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business Highlights

25 мар 2021 05:00:00 Источник Nasdaq GlobeNewswire

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency

11 мар 2021 06:30:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical Officer

04 фев 2021 05:00:00 Источник Nasdaq GlobeNewswire

Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

04 янв 2021 05:00:00 Источник Nasdaq GlobeNewswire